Compare Novartis with CEREBRA INTE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CEREBRA INTE - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CEREBRA INTE NOVARTIS/
CEREBRA INTE
 
P/E (TTM) x -445.6 20.1 - View Chart
P/BV x 2.4 1.9 125.9% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NOVARTIS   CEREBRA INTE
EQUITY SHARE DATA
    NOVARTIS
Mar-22
CEREBRA INTE
Mar-21
NOVARTIS/
CEREBRA INTE
5-Yr Chart
Click to enlarge
High Rs1,09964 1,717.2%   
Low Rs54717 3,217.6%   
Sales per share (Unadj.) Rs162.05.8 2,806.5%  
Earnings per share (Unadj.) Rs-1.50.1 -1,480.9%  
Cash flow per share (Unadj.) Rs2.40.1 1,750.3%  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %1.20-  
Book value per share (Unadj.) Rs281.124.1 1,165.0%  
Shares outstanding (eoy) m24.69121.19 20.4%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.17.0 72.4%   
Avg P/E ratio x-546.3398.1 -137.2%  
P/CF ratio (eoy) x342.7295.1 116.1%  
Price / Book Value ratio x2.91.7 174.4%  
Dividend payout %-663.70-   
Avg Mkt Cap Rs m20,3214,908 414.0%   
No. of employees `000NANA-   
Total wages/salary Rs m1,01992 1,112.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m3,999699 571.8%  
Other income Rs m3481 23,666.7%   
Total revenues Rs m4,347701 620.2%   
Gross profit Rs m-24186 -279.8%  
Depreciation Rs m974 2,244.2%   
Interest Rs m4844 109.1%   
Profit before tax Rs m-3839 -97.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-127 -3.7%   
Profit after tax Rs m-3712 -301.7%  
Gross profit margin %-6.012.3 -48.9%  
Effective tax rate %2.668.5 3.8%   
Net profit margin %-0.91.8 -52.8%  
BALANCE SHEET DATA
Current assets Rs m8,2682,127 388.8%   
Current liabilities Rs m3,345849 394.0%   
Net working cap to sales %123.1182.7 67.4%  
Current ratio x2.52.5 98.7%  
Inventory Days Days1,073458 234.6%  
Debtors Days Days418,891 0.5%  
Net fixed assets Rs m11,9931,706 703.1%   
Share capital Rs m1231,212 10.2%   
"Free" reserves Rs m6,8161,712 398.2%   
Net worth Rs m6,9392,924 237.3%   
Long term debt Rs m02 0.0%   
Total assets Rs m20,2613,832 528.7%  
Interest coverage x0.21.9 11.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.20.2 108.2%   
Return on assets %0.11.5 3.7%  
Return on equity %-0.50.4 -127.1%  
Return on capital %0.12.9 5.1%  
Exports to sales %8.80-   
Imports to sales %07.4 0.0%   
Exports (fob) Rs m353NA-   
Imports (cif) Rs mNA52 0.0%   
Fx inflow Rs m35310 3,442.9%   
Fx outflow Rs m79852 1,542.0%   
Net fx Rs m-445-41 1,072.3%   
CASH FLOW
From Operations Rs m387-54 -710.7%  
From Investments Rs m870-56 -1,564.6%  
From Financial Activity Rs m-356-64 557.7%  
Net Cashflow Rs m901-209 -431.4%  

Share Holding

Indian Promoters % 0.0 5.1 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.9 17.6 5.1%  
FIIs % 0.1 0.2 63.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 95.0 30.9%  
Shareholders   44,371 23,832 186.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   UNIPHOS ENT    MMTC    FUTURE CONSUMER    REDINGTON    HCL INFOSYS    



Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

How to Find the Next Multibagger Stock in the Market(Profit Hunter)

Jun 17, 2022

The #1 make or break factor in your portfolio you shouldn't ignore.

Is the Market Correction Over?(Fast Profits Daily)

Jun 17, 2022

In this video I'll show you why I think the market correction could be coming to an end.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 1, 2022 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS